Edition:
United States

Applied Genetic Technologies Corp (AGTC.OQ)

AGTC.OQ on NASDAQ Stock Exchange Global Market

6.86USD
1:40pm EST
Change (% chg)

$-0.04 (-0.58%)
Prev Close
$6.90
Open
$6.87
Day's High
$7.02
Day's Low
$6.76
Volume
8,644
Avg. Vol
24,035
52-wk High
$7.50
52-wk Low
$3.50

Latest Key Developments (Source: Significant Developments)

Applied Genetic Technologies Qtrly EPS $0.07
Thursday, 8 Nov 2018 07:00am EST 

Nov 8 (Reuters) - Applied Genetic Technologies Corp ::QUARTERLY REVENUE $14 MILLION VERSUS $10.3 MILLION.QTRLY EARNINGS PER SHARE $0.07.  Full Article

Applied Genetic Technologies Q4 Revenue $5.4 Mln Vs $39.5 Mln
Monday, 10 Sep 2018 04:03pm EDT 

Sept 10 (Reuters) - Applied Genetic Technologies Corp ::Q4 REVENUE $5.4 MILLION VERSUS $39.5 MILLION.Q4 REVENUE VIEW $8.5 MILLION -- THOMSON REUTERS I/B/E/S.EXPECTS TOTAL CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF JUNE 30, 2019 TO BE BETWEEN $65 AND $75 MILLION.  Full Article

Applied Genetic Technologies Reports Quarterly Loss Per Share Of ‍$ 0.29​
Friday, 9 Feb 2018 07:00am EST 

Feb 9 (Reuters) - Applied Genetic Technologies Corp ::QTRLY LOSS PER SHARE ‍$ 0.29​.‍APPLIED GENETIC TECHNOLOGIES QTRLY REVENUE $4.9 MILLION VERSUS $10.9 MILLION .AS OF DECEMBER 31, 2017, COMPANY'S CASH, CASH EQUIVALENTS, AND INVESTMENTS AMOUNTED TO $119.7 MILLION​.‍EXPECTS TOTAL CASH, CASH EQUIVALENTS, AND INVESTMENTS AS OF JUNE 30, 2018 TO BE BETWEEN $90 AND $100 MILLION​.Q2 EARNINGS PER SHARE VIEW $-0.19 -- THOMSON REUTERS I/B/E/S.  Full Article

Applied Genetic Technologies Reports Qtrly Loss Per Share Of ‍$0.29​
Friday, 9 Feb 2018 07:00am EST 

Feb 9 (Reuters) - Applied Genetic Technologies Corp ::QUARTERLY REVENUE $4.9 MILLION VERSUS $22.7 MILLION.QTRLY LOSS PER SHARE ‍$ 0.29​.‍AS OF DECEMBER 31, 2017, COMPANY'S CASH, CASH EQUIVALENTS, AND INVESTMENTS AMOUNTED TO $119.7 MILLION​.‍EXPECTS TOTAL CASH, CASH EQUIVALENTS, AND INVESTMENTS AS OF JUNE 30, 2018 TO BE BETWEEN $90 AND $100 MILLION​.  Full Article

Applied Genetic posts qtrly ‍net loss of $0.08​ per share
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Applied Genetic Technologies Corp :Quarterly revenue $10.3 million versus $11.8 million.Company expects total cash, cash equivalents, and investments as of june 30, 2018 to be between $85 and $100 million​.Qtrly ‍net loss per share $0.08​.  Full Article

Applied Genetic Technologies reports Q4 revenue of $8.3 mln
Wednesday, 13 Sep 2017 07:00am EDT 

Sept 13 (Reuters) - Applied Genetic Technologies Corp ::Q4 revenue $8.3 million versus $12.1 million.Q4 revenue view $11.9 million -- Thomson Reuters I/B/E/S.Q4 ‍loss per share $0.18​.Q4 earnings per share view $0.06 -- Thomson Reuters I/B/E/S.Expected to initiate patient enrollment in XLRP program in Q1 of 2018.Co believes its cash, cash equivalents, investments as of June 30 to be sufficient to fund planned programs for at least the next 2 years.  Full Article

Applied Genetic Technologies partners with the Foundation Fighting Blindness
Tuesday, 15 Aug 2017 07:00am EDT 

Aug 15 (Reuters) - Applied Genetic Technologies Corp ::AGTC and The Foundation Fighting Blindness announce partnership agreement.  Full Article

AGTC files investigational new drug application for treatment of x-linked retinitis pigmentosa
Thursday, 10 Aug 2017 07:00am EDT 

Aug 10 (Reuters) - Applied Genetic Technologies Corp :AGTC files investigational new drug application for the treatment of x-linked retinitis pigmentosa caused by mutations in the RPGR gene.Applied Genetic Technologies-to initiate study evaluating safety & efficacy of gene therapy for XLRP caused by RPGR gene mutations in U.S. in coming months​.  Full Article

AGTC announces FDA orphan drug designation for therapy to treat X-linked retinitis pigmentosa
Thursday, 3 Aug 2017 04:01pm EDT 

Aug 3 (Reuters) - Applied Genetic Technologies Corp ::AGTC announces U.S. FDA orphan drug designation for gene therapy to treat X-linked retinitis pigmentosa.  Full Article

AGTC appoints William Sullivan as chief financial officer
Wednesday, 2 Aug 2017 04:01pm EDT 

Aug 2 (Reuters) - Applied Genetic Technologies Corp :AGTC appoints William Sullivan as chief financial officer, Andrew Ashe named general counsel.Applied Genetic Technologies Corp - ‍ Larry Bullock, who has served as chief financial officer, is retiring​.  Full Article